- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc stock price live, this page displays NASDAQ SNDX stock exchange data. View the SNDX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Syndax Pharmaceuticals Inc real time stock price chart below.
What Is the Syndax Pharmaceuticals Inc Stock Price Today?
The Syndax Pharmaceuticals Inc stock price today is 9.48.
What Is the Stock Symbol for Syndax Pharmaceuticals Inc?
The stock symbol for Syndax Pharmaceuticals Inc is "SNDX."
What Stock Exchange Does Syndax Pharmaceuticals Inc Trade On?
Syndax Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Syndax Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Syndax Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SNDX quote. (ISIN: US87164F1057)
What Is the Syndax Pharmaceuticals Inc Stock Price Today?
The Syndax Pharmaceuticals Inc stock price today is 9.48.
What Is the Stock Symbol for Syndax Pharmaceuticals Inc?
The stock symbol for Syndax Pharmaceuticals Inc is "SNDX."
What Stock Exchange Does Syndax Pharmaceuticals Inc Trade On?
Syndax Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Syndax Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Syndax Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SNDX quote. (ISIN: US87164F1057)
9.48
-0.21(-2.17%)
Closed·
After Hours
9.48+0.02(+0.21%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.21
9.82
52 wk Range
8.58
25.07
SNDX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
SNDX is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
9.219.82
52 wk Range
8.5825.07
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SNDX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
34.18
Upside
+260.57%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales growth in the current year
Syndax Pharmaceuticals Company Profile
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory (R/R) acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.
Syndax Pharmaceuticals Inc SWOT Analysis
FDA Approvals Boost | Explore how Syndax's recent FDA approvals for Revuforj and Niktimvo have strengthened its market position and set the stage for potential revenue growth |
Commercial Strategy | Delve into Syndax's market penetration efforts, with early success in Tier 1 and Tier 2 accounts and positive launch dynamics for Revuforj in AML treatment |
Clinical Advancements | Learn about Syndax's promising clinical trial results, including expanded datasets for NPM1-mutant AML and strong BEAT AML data, bolstering confidence in its pipeline |
Financial Outlook | Analysts project 233% revenue growth for FY2025, with an average price target of $33, despite near-term profitability challenges and negative EPS forecasts |
Syndax Pharmaceuticals Inc Earnings Call Summary for Q1/2025
- Syndax Pharmaceuticals (SNDX) beats Q1 2025 EPS estimates, reporting -$0.98 vs -$1.24 forecast; revenue of $20.04M exceeds $14.84M expectation
- Stock rises 1.03% in aftermarket trading to $13.71; company maintains strong liquidity with current ratio of 5.82
- RevuForge and Nictimvo show strong market potential; CEO highlights 'two de-risked medicines with multibillion-dollar potential'
- Company holds $602.1M in cash and equivalents; aims for profitability through strategic product launches and market expansions
- Ongoing net losses and dependence on collaboration revenue pose challenges; success of clinical trials and product launches remains uncertain
Last Updated: 06-05-2025, 03:10 am
Read Full TranscriptCompare SNDX to Peers and Sector
Metrics to compare | SNDX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSNDXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.5x | −9.3x | −0.5x | |
PEG Ratio | 0.13 | −0.06 | 0.00 | |
Price/Book | 3.8x | 1.3x | 2.6x | |
Price / LTM Sales | 18.7x | 4.0x | 3.0x | |
Upside (Analyst Target) | 290.3% | 238.5% | 52.4% | |
Fair Value Upside | Unlock | 43.0% | 8.7% | Unlock |
Analyst Ratings
11 Buy
1 Hold
0 Sell
Ratings:
12 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 34.18
(+260.57% Upside)
Earnings
Latest Release
May 05, 2025
EPS / Forecast
-0.98 / -1.24
Revenue / Forecast
20.04M / 14.84M
FAQ
What Is the Syndax Pharmaceuticals (SNDX) Stock Price Today?
The Syndax Pharmaceuticals stock price today is 9.48.
What Stock Exchange Does Syndax Pharmaceuticals Trade On?
Syndax Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Syndax Pharmaceuticals?
The stock symbol for Syndax Pharmaceuticals is "SNDX."
What Is the Syndax Pharmaceuticals Market Cap?
As of today, Syndax Pharmaceuticals market cap is 815.73M.
What Is Syndax Pharmaceuticals's Earnings Per Share (TTM)?
The Syndax Pharmaceuticals EPS (TTM) is -3.86.
When Is the Next Syndax Pharmaceuticals Earnings Date?
Syndax Pharmaceuticals will release its next earnings report on 10 Aug 2025.
From a Technical Analysis Perspective, Is SNDX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Syndax Pharmaceuticals Stock Split?
Syndax Pharmaceuticals has split 0 times.
How Many Employees Does Syndax Pharmaceuticals Have?
Syndax Pharmaceuticals has 270 employees.
What is the current trading status of Syndax Pharmaceuticals (SNDX)?
As of 22 Jun 2025, Syndax Pharmaceuticals (SNDX) is trading at a price of 9.48, with a previous close of 9.69. The stock has fluctuated within a day range of 9.21 to 9.82, while its 52-week range spans from 8.58 to 25.07.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.